FDA
-
-
-
-
-
-
-
Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026
-
-
-
-
-
-
-
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
-
-
-
-
-
-
-
Humacyte adds two nephrologists as advisors for dialysis product push
-
-
-
-
-
-
-
Humacyte announces public offering of common stock
-
-
-
-
-
-
-
Humacyte presents research on dialysis access vessel self-repair at VASA meeting
-
-
-
-
-
-
-
Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026
-
-
-
-
-
-
-
Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair
-
335,437 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


